Last reviewed · How we verify
Advair 250 - matched
Advair 250, marketed by Milton S. Hershey Medical Center, is a well-established respiratory therapy with a strong presence in the market. The key composition patent, set to expire in 2028, provides a significant period of exclusivity and competitive advantage. The primary risk lies in potential generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Advair 250 - matched |
|---|---|
| Also known as | fluticasone/salmeterol 250/50 |
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep (PHASE4)
- A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial (PHASE4)
- Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD (PHASE3)
- Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD (PHASE2)
- The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Advair 250 - matched CI brief — competitive landscape report
- Advair 250 - matched updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI